Free tracker

GLP-1 Pipeline Tracker for Weight Loss Drugs

Only 5 of the 79 drugs on this list hold an FDA approval for weight management. Look up any of the others by name, company or class to see the stage it has reached and the last step we could confirm.

Go to what each status means, the seven drug classes or FAQs

Find a drug

Data as of November 19, 2026

  • Approved 13
  • Submitted 10
  • Phase 3 19
  • Phase 2 18
  • Phase 1 7
  • Discontinued 12

Showing 79 drugs

GLP-1 pipeline drugs for weight loss, listing the status, class, company and route of each. Data as of November 19, 2026.
DrugStatusClassCompanyRouteWhat we confirmed
GLP-1 RA 22 listed
Albiglutide TanzeumDiscontinuedGLP-1 RAGSKInjection, weeklyThe FDA drug database shows Tanzeum, a diabetes drug, as discontinued. Its label last changed in December 2017. Source, Albiglutide
BeinaglutideApprovedGLP-1 RAShanghai BenemaeInjection, three times dailyBenemae announced its Chinese registration certificate for weight loss on July 28, 2023. Source, Beinaglutide
Berobenatide PF-08653944; MET-097iPhase 3GLP-1 RAPfizerInjection, weekly or monthlyIn Phase 3 on Pfizer’s November 3, 2026 pipeline. Thirteen Phase 3 trials are registered, the first from December 2025. Source, Berobenatide
Bofanglutide GZR18GLP-1 RAGan & Lee PharmaceuticalsInjection, every two weeksChina’s drug regulator took the weight management application for review on September 2, 2026. Source, Bofanglutide
Dulaglutide TrulicityApprovedGLP-1 RAEli LillyInjection, weeklyThe FDA cleared Trulicity for type 2 diabetes on September 18, 2014. It has no weight loss approval. Source, Dulaglutide
Ecnoglutide XW003ApprovedGLP-1 RASciwind BiosciencesInjection, weeklySciwind announced Chinese approval for chronic weight management in adults on March 6, 2026. Source, Ecnoglutide
EfpeglenatideApprovedGLP-1 RAHanmi PharmaceuticalInjection, weeklySouth Korea’s drug ministry licensed it as an obesity treatment on October 7, 2026. Source, Efpeglenatide
Efsubaglutide alfa supaglutideApprovedGLP-1 RAInnogenInjection, weeklySold in China for type 2 diabetes. Its obesity trial finished main follow-up in July 2026, with results due by year end. Source, Efsubaglutide alfa
Exenatide Byetta; BydureonDiscontinuedGLP-1 RAAstraZenecaInjection, twice daily or weeklyByetta, Bydureon and Bydureon BCise each show as discontinued in the FDA drug database. Source, Exenatide
HDM1702 semaglutide injection (Huadong)GLP-1 RAHuadong MedicineInjection, weeklyHuadong’s own version of semaglutide. China took its weight management application for review on April 14, 2026. Source, HDM1702
Liraglutide Victoza; SaxendaApprovedGLP-1 RANovo NordiskInjection, dailyThe FDA cleared Saxenda for weight management on December 23, 2014. Victoza, for diabetes, dates from January 2010. Source, Liraglutide
Lixisenatide Adlyxin; LyxumiaDiscontinuedGLP-1 RASanofiInjection, dailyThe European Commission withdrew the Lyxumia license on December 18, 2025, at Sanofi’s request. Source, Lixisenatide
Loxenatide PEG-loxenatide; PEX168ApprovedGLP-1 RAJiangsu HansohInjection, weeklyCleared in China on May 5, 2019, for type 2 diabetes only. Source, Loxenatide
MET-224o PF-08656796DiscontinuedGLP-1 RAPfizerOralDropped during Phase 1, according to the pipeline Pfizer published on August 4, 2026. Source, MET-224o
Noiiglutide SHR20004Phase 2GLP-1 RAJiangsu HengruiInjectionThe obesity Phase 2 record has had no update since March 2022. A separate Phase 3 diabetes trial is finished. Source, Noiiglutide
SAL0150Phase 1GLP-1 RAShenzhen SalubrisOral, weekly or every two weeksA peptide tablet cleared for human trials in China in March 2026. A Phase 2 diabetes trial is registered but not open. Source, SAL0150
Semaglutide Ozempic; WegovyApprovedGLP-1 RANovo NordiskInjection, weeklyThe FDA cleared Wegovy for weight management on June 4, 2021. Ozempic, for type 2 diabetes, dates from December 2017. Source, Semaglutide
Semaglutide oral Rybelsus; Wegovy tabletsApprovedGLP-1 RANovo NordiskOral, dailyThe FDA cleared the Wegovy tablet on December 22, 2025. Rybelsus, the diabetes tablet, dates from September 2019. Source, Semaglutide oral
TaspoglutideDiscontinuedGLP-1 RARocheInjection, weeklyRoche handed the drug back to Ipsen in February 2011 after nausea and hypersensitivity problems in trials. Source, Taspoglutide
TG103 efmedaglutide alfaGLP-1 RACSPC PharmaceuticalInjection, weeklyChina took the weight management application for review on October 13, 2025, and a diabetes application in June 2026. Source, TG103
Visepegenatide PB-119ApprovedGLP-1 RAPegBioInjection, weeklyCleared in China in November 2025 as a weekly type 2 diabetes drug. It has no weight loss approval. Source, Visepegenatide
VRB-101 oral ecnoglutidePhase 2GLP-1 RAVerdiva BioOral, weeklyOne Phase 2b trial is finished. A second was stopped in 2026 as a business decision, not over safety. Source, VRB-101
GLP-1/GIP 11 listed
BGM0504GLP-1/GIPBrightGeneInjection, weeklyBrightGene said on November 11, 2026 that its Chinese weight loss application, accepted in June, was still in review. Source, BGM0504
Brenipatide LY3537031Phase 1GLP-1/GIPEli LillyInjectionA Phase 1 study in people with overweight or obesity is under way. Lilly’s Phase 3 trials test it for alcohol use disorder and for depression. Source, Brenipatide
Enicepatide CT-388; RO7795068Phase 3GLP-1/GIPRocheInjection, weeklyThree Phase 3 trials are recruiting. The first opened on March 16, 2026. Source, Enicepatide
HDM1005 poterepatidePhase 3GLP-1/GIPHuadong MedicineInjection, weeklyHuadong’s 2026 half-year report says the Phase 3 weight management trial has finished enrolling. Source, HDM1005
NNC0519-0130Phase 2GLP-1/GIPNovo NordiskInjection, weeklyThe obesity Phase 2 trial is finished. Novo’s third quarter 2026 investor slides do not mention the drug. Source, NNC0519-0130
Olatorepatide HS-20094GLP-1/GIPHansoh Pharma; RegeneronInjection, weeklyChina took Hansoh’s application for review on June 4, 2026. Regeneron’s first Phase 3 trial is registered but not open. Source, Olatorepatide
RAY1225 bilpatidePhase 3GLP-1/GIPGuangdong Zhongsheng PharmaceuticalInjection, every two weeksIn October 2026 a 52 week Phase 3 study in China hit its primary target. No application had been filed by then. Source, RAY1225
Ribupatide HRS9531; KAI-9531GLP-1/GIPJiangsu Hengrui; KaileraInjection, weeklyHengrui said in July 2026 that the Chinese application accepted in September 2025 was still in review. Source, Ribupatide
Tirzepatide Mounjaro; ZepboundApprovedGLP-1/GIPEli LillyInjection, weeklyThe FDA cleared Zepbound for weight management on November 8, 2023. Mounjaro, for type 2 diabetes, dates from May 2022. Source, Tirzepatide
VK2735Phase 3GLP-1/GIPViking TherapeuticsInjection, weeklyBoth VANQUISH Phase 3 trials opened in June 2025 and have finished enrolling. Source, VK2735
VK2735 oralPhase 3GLP-1/GIPViking TherapeuticsOral, dailyThe two SUNRISE Phase 3 trials of the daily tablet were listed as recruiting on November 16, 2026. Source, VK2735 oral
GLP-1/glucagon 6 listed
Cotadutide MEDI0382DiscontinuedGLP-1/glucagonAstraZenecaInjection, dailyAstraZeneca reported in April 2023 that it had dropped this daily injection to focus on a weekly drug, AZD9550. Source, Cotadutide
DA-1726Phase 1GLP-1/glucagonMetaVia; Dong-A STInjection, weeklyMetaVia reported 16 week Phase 1 data on November 13, 2026. A Phase 2 liver disease trial is planned for the second half of 2027. Source, DA-1726
Efinopegdutide MK-6024Phase 2GLP-1/glucagonMerck & Co.Injection, weeklyOn Merck’s pipeline of November 2, 2026 it sits in Phase 2 for MASH, a liver disease. No obesity trial is open. Source, Efinopegdutide
Mazdutide IBI362ApprovedGLP-1/glucagonInnovent BiologicsInjection, weeklyInnovent announced Chinese approval for chronic weight management on June 27, 2025. Source, Mazdutide
Pemvidutide ALT-801Phase 2GLP-1/glucagonAltimmuneInjection, weeklyThe obesity Phase 2 trial ended in 2023. Altimmune’s Phase 3 trial is in MASH, a liver disease. Source, Pemvidutide
Survodutide BI 456906Phase 3GLP-1/glucagonBoehringer IngelheimInjection, weeklyAfter Phase 3 heart safety results on November 9, 2026, the company said it is moving ahead with regulatory submissions. Source, Survodutide
GIP/GLP-1/glucagon 4 listed
Efocipegtrutide HM15211Phase 2GIP/GLP-1/glucagonHanmi PharmaceuticalInjection, weeklyIts finished Phase 2 trial was in the liver disease MASH. No obesity trial beyond Phase 1 is registered. Source, Efocipegtrutide
MWN101Phase 2GIP/GLP-1/glucagonShanghai Minwei Biotechnology (Lepu Medical)InjectionLepu Medical’s 2026 half-year report shows it through Phase 2. A sister drug, MWN109, has entered Phase 3. Source, MWN101
Retatrutide LY3437943Phase 3GIP/GLP-1/glucagonEli LillyInjection, weeklyLilly has reported several positive Phase 3 obesity trials. It aims to send its FDA application in the first three months of 2027. Source, Retatrutide
UBT251Phase 3GIP/GLP-1/glucagonUnited Laboratories; Novo NordiskInjection, weeklyChinese Phase 3 testing for obesity started on September 4, 2026. Novo Nordisk runs earlier-stage trials elsewhere. Source, UBT251
Amylin & combos 11 listed
ABBV-295 GUB014295Phase 2Amylin & combosAbbVieInjectionAbbVie calls it a long-acting amylin analog. A Phase 2 dose-finding trial opened on August 4, 2026. Source, ABBV-295
ACCG-2671Phase 1Amylin & combosStructure TherapeuticsOralStructure was running the multiple-dose stage in November 2026 and expects results in the first half of 2027. Source, ACCG-2671
CagrilintidePhase 3Amylin & combosNovo NordiskInjection, weeklyThe RENEW Phase 3 trials of cagrilintide by itself opened on November 5, 2025 and have finished enrolling. Source, Cagrilintide
CagriSema cagrilintide + semaglutideAmylin & combosNovo NordiskInjection, weeklyFiled with the FDA in December 2025. On November 14, 2026 Novo still expected a decision before the end of the year. Source, CagriSema
Eloralintide LY3841136Phase 3Amylin & combosEli LillyInjection, weeklyShown in Phase 3 for obesity on Lilly’s pipeline dated October 29, 2026. Its first Phase 3 trial opened in December 2025. Source, Eloralintide
EloraTZP LY900043; eloralintide + tirzepatidePhase 3Amylin & combosEli LillyInjectionThe first Phase 3 trial of this combined injection opened on October 16, 2026. A second is due to open in December. Source, EloraTZP
MET-233i PF-08653945Phase 2Amylin & combosPfizerInjection, weekly or monthlyIn Phase 2 on Pfizer’s November 3, 2026 pipeline, both by itself and combined with berobenatide. Source, MET-233i
Petrelintide ZP8396; RO7895515Phase 3Amylin & combosZealand Pharma; RocheInjection, weeklyRoche opened three Phase 3 trials between September 30 and October 9, 2026, with Zealand as its partner. Source, Petrelintide
Pramlintide SymlinDiscontinuedAmylin & combosAstraZenecaInjection, at mealtimesSymlin, cleared in 2005 for people using mealtime insulin, shows as discontinued in the FDA drug database. Source, Pramlintide
VRB-103Phase 1Amylin & combosVerdiva BioOral, weeklyIts first human study, by itself and with oral ecnoglutide, opened in July 2026 and is recruiting. Source, VRB-103
Zenagamtide amycretin; NNC0487-0111Phase 3Amylin & combosNovo NordiskInjection, weeklyThe AMAZE Phase 3 program opened on February 24, 2026. A Phase 3 trial of a tablet form followed in September. Source, Zenagamtide
Oral small molecule 16 listed
Aleniglipron GSBR-1290Phase 3Oral small moleculeStructure TherapeuticsOral, dailyTwo ACCOMPLISH Phase 3 trials are enrolling. Structure expects the first results in the second half of 2028. Source, Aleniglipron
ASC30 oralPhase 3Oral small moleculeAscletisOral, dailyTwo AURORA Phase 3 trials opened at the end of August 2026 and are recruiting. Source, ASC30 oral
Danuglipron PF-06882961DiscontinuedOral small moleculePfizerOralPfizer stopped work on April 14, 2025 after one trial participant had a possible drug-related liver injury. Source, Danuglipron
Elecoglipron AZD5004; ECC5004Phase 3Oral small moleculeAstraZenecaOral, dailyNine Phase 3 trials are recruiting. The weight management program opened on June 29, 2026. Source, Elecoglipron
HDM1002 conveglipronOral small moleculeHuadong MedicineOral, dailyOn November 2, 2026 China agreed to review it as a long-term weight control drug for adults. Source, HDM1002
Lotiglipron PF-07081532DiscontinuedOral small moleculePfizerOralPfizer stopped work on June 26, 2023 after raised liver enzymes showed up in early trials. Source, Lotiglipron
LY4086940Phase 1Oral small moleculeEli LillyOralPhase 1 is finished. A Phase 2 obesity trial was posted in October 2026 and is not yet recruiting. Source, LY4086940
MDR-001Phase 3Oral small moleculeMindRankOralMindRank announced the first patient dosed in its Phase 3 trial in China on February 26, 2026. Source, MDR-001
Naperiglipron LY3549492Phase 2Oral small moleculeEli LillyOral, dailyStill in Phase 2 on Lilly’s October 29, 2026 pipeline. Two other Phase 2 studies were ended for business reasons. Source, Naperiglipron
Orforglipron Foundayo; LY3502970ApprovedOral small moleculeEli LillyOral, dailyThe FDA cleared Foundayo for weight management on April 1, 2026. Source, Orforglipron
RGT-075 RGT001-075Phase 2Oral small moleculeRegor PharmaceuticalsOral, dailyBoth of its Phase 2 obesity trials are finished. The registry entry for the newer one last changed in May 2026. Source, RGT-075
Safiglipron HRS-7535; KAI-7535Oral small moleculeJiangsu Hengrui; KaileraOral, dailyChina took the weight management application for review in early September 2026. Source, Safiglipron
TERN-601DiscontinuedOral small moleculeTerns Pharmaceuticals (Merck)Oral, dailyWork ended after liver safety findings in Phase 2. Merck completed its purchase of Terns on May 5, 2026. Source, TERN-601
Tifeglipron CT-996; RO7795081Phase 2Oral small moleculeRocheOral, dailyThe Phase 2 obesity trial is finished and a Phase 2 diabetes trial is still recruiting. Nothing in Phase 3 is on the registry. Source, Tifeglipron
TQF3250Phase 1Oral small moleculeSino Biopharm (Chia Tai Tianqing)Oral, dailyA 12 week Phase 1b study in people with overweight or obesity opened on September 29, 2026. Source, TQF3250
VCT220 CX11Oral small moleculeVincentage Pharma; CorxelOral, dailyChina’s drug review center lists the application as accepted on July 20, 2026, under number CXHS2600104. Source, VCT220
Other 9 listed
Acmopatide CT-868; RO7795074Phase 2OtherRocheInjection, dailyIts most recent Phase 2 study, now finished, enrolled adults who have type 1 diabetes plus overweight or obesity. Source, Acmopatide
ApitegromabPhase 2OtherScholar RockInjection, IV every 4 weeksA Phase 2 trial alongside tirzepatide is finished. Its Phase 3 work is in spinal muscular atrophy. Source, Apitegromab
Bimagrumab LY3985863Phase 2OtherEli LillyInjectionAn antibody listed in Phase 2 for obesity on Lilly’s October 29, 2026 pipeline. Source, Bimagrumab
Dapiglutide ZP7570DiscontinuedOtherZealand PharmaInjection, weeklyZealand’s pipeline lists this GLP-1 and GLP-2 drug as paused after a Phase 1b trial. Source, Dapiglutide
EnobosarmPhase 2OtherVeruOral, dailyA Phase 2b trial with semaglutide opened on March 26, 2026 and has finished enrolling. Source, Enobosarm
GaretosmabPhase 2OtherRegeneronInjectionTested only with trevogrumab and semaglutide, in a Phase 2 trial that is now finished. Source, Garetosmab
Maridebart cafraglutide MariTide; AMG 133Phase 3OtherAmgenInjection, every 4 weeksTwelve Phase 3 trials are under way. The first opened on March 12, 2025. Source, Maridebart cafraglutide
PF-07976016DiscontinuedOtherPfizerOralA GIP receptor blocker. Pfizer’s August 4, 2026 pipeline lists it among programs dropped in Phase 2. Source, PF-07976016
TrevogrumabPhase 2OtherRegeneronInjectionIts Phase 2 trial, given with semaglutide and in some arms garetosmab, is finished. The record was updated on November 12, 2026. Source, Trevogrumab

Submitted covers any marketing application that a regulator has agreed to review. Some trackers call this stage Filed. Approved counts an approval in any one country, so read the note to see which country and which use. A drug name opens its ClinicalTrials.gov search in a new tab, and each Source link opens the document we read.

How does the GLP-1 pipeline tracker work?

Each row is one drug, and each drug carries one status: the furthest point it has reached as a weight loss treatment. The list view shows all 79 drugs with the class, the company, how the drug is taken and a one-line note on the last step we could confirm. The by-stage view sets the same drugs out in columns from earliest to latest, so you can count how many sit one step from a decision.

The search box matches a drug name, a brand name, a research code such as LY3437943, a company or a class. The Approved, Oral and Injectable buttons narrow the results, and you can press more than one. The by-stage view adds Phase 1 drugs only after you tick Show Phase 1 drugs, and it never draws discontinued ones. Trial stages come from ClinicalTrials.gov, the U.S. registry of clinical studies, and from company and regulator documents.1

What does each status mean?

The status shows how much testing a drug has passed, not how good the drug is. The FDA describes the three trial phases this way.2

StatusWhat is being testedTypical size and lengthWhat usually happens next
Phase 1Safety and doseBetween 20 and 100 volunteers, for several monthsAbout 70% of drugs go on to Phase 2
Phase 2Whether the drug works, and its side effectsAs many as several hundred patients, for several months to 2 yearsAbout 33% go on to Phase 3
Phase 3Benefit in a larger group, with adverse reactions trackedBetween 300 and 3,000 volunteers, for 1 to 4 yearsAbout 25% to 30% go on to the next step
SubmittedA regulator is reading the full applicationAt the FDA, 6 to 10 months once the application is complete3Approval or refusal
ApprovedNothing further is needed to sell the drug in that countryNot applicableThe note names the country and the approved use
DiscontinuedNothing. The company stopped or paused work, or took the product off the marketNot applicableThe drug stays on the list as a record

Those percentages describe new drugs in general, not weight loss drugs in particular. The plain reading is that most names in the Phase 1 and Phase 2 columns will never reach a pharmacy.

How we chose each status

  • The status is for weight management. Where a drug’s late-stage trials are in another disease, the row shows its obesity stage and the note names the rest. Brenipatide has Phase 3 trials in alcohol use disorder and depression, so it appears here at its obesity stage, Phase 1.
  • A planned trial does not count. A study that is registered but not yet recruiting does not move a drug up. LY4086940 has a Phase 2 trial on the registry and stays in Phase 1 until that trial opens.
  • Approved does not always mean approved for weight loss. Dulaglutide, loxenatide, visepegenatide and efsubaglutide alfa are approved only for type 2 diabetes, and their notes say so.

Phase and timing can change. Companies move trial dates, pause programs and drop drugs with little notice. Each row records what we could confirm on November 19, 2026. It is not a forecast.

What drug classes are in the GLP-1 pipeline?

The 79 drugs fall into seven classes, named for the hormone signals they copy or block. Class labels follow each developer’s own description or its trial record, both linked from the table.

ClassWhat the drugs act onOn the listExamples
GLP-1 RAThe GLP-1 receptor alone. RA is short for receptor agonist22Semaglutide (Ozempic®, Wegovy®), liraglutide, berobenatide
GLP-1/GIPThe GLP-1 and GIP receptors11Tirzepatide (Mounjaro®, Zepbound®), enicepatide, VK2735
GLP-1/glucagonThe GLP-1 and glucagon receptors6Survodutide, mazdutide, cotadutide
GIP/GLP-1/glucagonAll three receptors, which is why these are called triple agonists4Retatrutide, UBT251
Amylin and combinationsAmylin receptors, either alone or paired with a GLP-1 drug11Cagrilintide, CagriSema, eloralintide, petrelintide
Oral small moleculeThe GLP-1 receptor, using a pill that is not a peptide16Orforglipron (Foundayo®), aleniglipron, elecoglipron
OtherDifferent targets, including drugs tested alongside a GLP-1 to help keep muscle9Maridebart cafraglutide, bimagrumab, enobosarm

Not every pill sits in the Oral small molecule class. Oral semaglutide, VRB-101 and SAL0150 are peptides made into tablets, so they are filed with the GLP-1 RA drugs. Press the Oral button to see all 25 drugs taken by mouth, whatever their class. The other 54 are injections, most of them weekly.

More targets do not make a drug better by default. Only a trial that compares two drugs head to head can show that. For a plain account of how the approved drugs work, see our pages on semaglutide and tirzepatide.

What does the pipeline mean if you want treatment now?

It means very little for a decision you make this year. Nothing in the Phase 1, Phase 2, Phase 3 or Submitted columns can be prescribed in the United States. Investigational drugs are not available by prescription, and the usual way to receive one is to enroll in its clinical trial. The FDA’s expanded access route exists for people with a serious or immediately life-threatening condition and no comparable alternative, which is not how weight loss drugs are normally reached.4

Be careful with websites that sell pipeline drugs. According to the FDA, federal law does not allow retatrutide or cagrilintide in compounding, and neither has been found safe and effective for any condition. It has also warned companies that sold unapproved retatrutide, survodutide and mazdutide labeled “for research purposes” or “not for human consumption.”5

What an AM Rx provider can prescribe today

AM Rx providers are U.S.-licensed, board-certified physicians and nurse practitioners. When one of them finds it appropriate for you, they can prescribe brand-name Zepbound, Wegovy, Mounjaro or Ozempic, or compounded semaglutide or compounded tirzepatide. Mounjaro and Ozempic hold FDA approval for type 2 diabetes only, not for weight loss, so prescribing either one for weight is off-label. No compounded medication is FDA-approved. The FDA does not review compounded drugs for safety, for effectiveness or for quality.

As of November 2026, an AM Rx membership costs $39 in the first month and $135 a month from then on, and medication is billed separately. Our coordination team submits prior authorizations for brand-name medication. If your plan covers the medication, the monthly copay can be as low as $25. Compounded semaglutide costs $199 for a single month, and on a 3-month supply the price starts at $106 a month. Compounded tirzepatide costs $329 for a single month, and on a 3-month supply the price starts at $216 a month.

Two more tools answer the next questions. The GLP-1 supply tracker reports any approved medication that is on the FDA shortage list. The insurance coverage checker walks through how we find out what your plan pays for.

Important safety information for approved GLP-1 medicines. Zepbound and Wegovy carry a boxed warning: they caused thyroid C-cell tumors in rodents, and it is not known whether they do so in people. Do not use them if you or a family member has had medullary thyroid carcinoma, or if you have Multiple Endocrine Neoplasia syndrome type 2, known as MEN 2. Serious risks include pancreatitis, gallbladder problems, kidney injury from dehydration, severe stomach problems and low blood sugar when taken with insulin or a sulfonylurea. Nausea, diarrhea, vomiting and constipation are among the most common side effects.6,7 In November 2026 the FDA also told makers of GLP-1 drugs to add a warning about NAION, a rare eye condition that can cause sudden vision loss.8 Read the full safety sections for Zepbound and Wegovy.

GLP-1 pipeline tracker FAQs

Which weight loss drugs could the FDA decide on next?

CagriSema is the only drug on this list under FDA review. Novo Nordisk filed it in December 2025 and, on November 14, 2026, still expected a decision before the end of the year.9 Eli Lilly plans to submit retatrutide in the first three months of 2027,10 and Boehringer Ingelheim says it is moving ahead with submissions for survodutide.11 None of these dates is a promise. Reviews can run long, and an application can be refused.

Is retatrutide available by prescription yet?

No. Retatrutide is still in Phase 3 trials and no regulator has approved it, so no pharmacy can fill a prescription for it and AM Rx providers cannot prescribe it. The FDA has stated that federal law does not allow retatrutide in compounding, and it has warned companies that market the drug.5 Lilly plans to ask the FDA for approval early in 2027, and a review takes months after that.3,10

Is there an approved GLP-1 pill for weight loss?

Yes, there are two. The FDA approved Wegovy tablets, an oral form of semaglutide, on December 22, 2025, and Foundayo (orforglipron), a once-daily tablet, on April 1, 2026.12,13 The other 23 oral drugs on this list are in trials, under review outside the United States or discontinued. Press the Oral button in the tracker to see all of them with their current status.

Why does the tracker list approved drugs that U.S. pharmacies do not carry?

Because the Approved label here counts approval by any one country’s regulator, and that is not always the FDA. Seven of the 13 approved drugs on the list have no FDA approval, including mazdutide and ecnoglutide in China and efpeglenatide in South Korea. A provider in the United States cannot prescribe them. The note beside each drug names the country and the use that was approved.

Does Submitted mean a drug will be approved?

No. Submitted means a regulator has accepted a marketing application and begun its review. The FDA says its review team has 6 to 10 months to decide once an application is complete, and the answer can be no.3 Nine of the 10 submitted drugs on this list are under review in China, so even an approval there would not make them available in the United States.

How can I find a clinical trial for a new weight loss drug?

Select any drug name in the tracker. It opens a ClinicalTrials.gov search for that drug, and each study record shows who can join, where the study runs and whether it is recruiting.1 Trials have strict entry rules, and you may be given a placebo. Talk with your own doctor before you enroll, especially if you take other medication.

How current is the tracker, and how was it checked?

Every row was checked on November 19, 2026 against a primary source: a company pipeline page, press release or filing, a regulator’s database, or a trial registry. Each note links to the document we read. A status can change the next day, so treat the date above the table as the limit of what we know, and confirm anything important with the source.

Sources

  1. National Library of Medicine. ClinicalTrials.gov. Trial records read on November 19, 2026. https://clinicaltrials.gov/
  2. U.S. Food and Drug Administration. The Drug Development Process, Step 3: Clinical Research. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
  3. U.S. Food and Drug Administration. The Drug Development Process, Step 4: FDA Drug Review. https://www.fda.gov/patients/drug-development-process/step-4-fda-drug-review
  4. U.S. Food and Drug Administration. Expanded Access. Content current as of October 22, 2026. https://www.fda.gov/news-events/public-health-focus/expanded-access
  5. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of October 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  6. Zepbound (tirzepatide) injection. Prescribing Information. Eli Lilly and Company. Revised 8/2026. https://pi.lilly.com/us/zepbound-uspi.pdf
  7. Wegovy (semaglutide) injection and tablets. Prescribing Information. Novo Nordisk. Revised 6/2026. https://www.novo-pi.com/wegovy.pdf
  8. U.S. Food and Drug Administration. FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition. Drug Safety Communication, November 9, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
  9. Novo Nordisk. CagriSema REDEFINE 9 trial data presented at ObesityWeek 2026. Press release, November 14, 2026. https://www.novonordisk-us.com/media/press-releases/cagrisema-redefine-9-trial-obesityweek-2026.html
  10. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. Press release, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
  11. Boehringer Ingelheim. Survodutide SYNCHRONIZE-CVOT trial results. Press release, November 9, 2026. https://www.globenewswire.com/fr/news-release/2026/11/09/3398586/0/en/boehringer-ingelheim-s-survodutide-is-the-first-glucagon-glp-1-dual-agonist-to-demonstrate-a-favorable-cardiovascular-safety-profile-in-global-phase-iii-synchronize-cvot-trial-alon.html
  12. U.S. Food and Drug Administration. Drugs@FDA: Wegovy tablets, NDA 218316. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316
  13. U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. Press announcement, April 1, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program

The source for each drug’s status is linked from its row in the table. This page is general information, not medical advice. Drugs described as investigational have not been approved and are not available from AM Rx.

Ask a provider about the GLP-1 options you can fill now

The health questionnaire takes a few minutes and is read by a licensed provider. Your first month of AM Rx membership is $39.

Get Started
A man at home smiling at his laptop
Your care team

Care that does not wait on a drug still in trials

A licensed AM Rx provider reviews your health history online, usually within 1 to 2 business days, and tells you whether a GLP-1 medication you can fill now is a fit.

50 states and DCU.S.-licensed physicians and nurse practitioners, wherever you live
No appointment to bookA provider reads your intake online and replies by secure message
Open every dayPhone support Monday to Friday 9am to 8pm ET, weekends 12pm to 8pm ET

The AM Rx care team checks the medical content of this page against FDA prescribing information and published clinical trials. It is general health education and does not replace advice from your own provider.

AM Rx members

AM Rx members, in their own words

One of the things I appreciate most about semaglutide is its convenience. The once-weekly dosing schedule has made it incredibly easy to integrate into my routine. It's a relief to know that I don't have to worry about multiple daily injections or complicated medication schedules.
Michelle, 33 | Lost 48 pounds
I started semaglutide at the recommendation of my AM Rx provider and I'm so happy with that decision. I signed up for their weight loss program and they've been giving me everything I need to make better lifestyle choices to get results that last. And the program's super affordable. 10/10 I can't recommend this enough.
Michael, 37 | Lost 29 pounds
Getting support a weight loss program has always been hard for me. I had been wanting to start one with a medication component for a while and AM Rx was the first one that made it easy for me with weight loss shots sent to me. They made it SO affordable and the medical team is great.
Susanne, 60 | Lost 33 pounds
Since I started AM Rx, I have already lost 35 pounds and feel so much better. My doctor also helped me get a prescription for ozempic and he is always available to answer my questions in the message portal. This made me feel a lot more comfortable and excited to lose weight.
Rachel | AM Rx Member
The weight loss program is fantastic. Everyone has been so helpful and has helped me feel much more excited about the process. I was nervous to see my weight loss treatment plan, since I have done programs in the past, but they always wanted me to make drastic changes. I mentioned all of this to my weight loss coach and she was very understanding and made a customized plan for me.
John | AM Rx Member
I've been a member for 6 months now and have received all my medication every 3 months. Everyone has been so helpful and my care team is always available to help me!
Sara | AM Rx Member

Individual results may vary. These reviews describe the experience of individual AM Rx members and do not promise any result. Medication is prescribed only if a licensed provider considers it appropriate.

Medications

The GLP-1 medications AM Rx providers prescribe

Four brand-name medications and two compounded options. Which one you are offered depends on your health history and a licensed provider’s judgment, and our insurance coordinators file the prior authorization when a brand-name drug is prescribed.

A partner pharmacy prepares compounded medication for one patient’s prescription at a time. Compounded drugs are not FDA-approved: the FDA does not review them for safety, effectiveness or quality. AM Rx membership costs $39 for the first month and $135 a month after that, and is charged separately from medication. Nothing is prescribed unless a licensed provider finds it appropriate.